# Compare Thymulin and Thymosin Alpha-1 — Peptide Care Now

> A side-by-side comparison of two Immune & Thymic research peptides — thymulin and thymosin alpha-1 — across peptide class, evidence base, administration studied, regulatory status and key cautions.

Where thymulin and thymosin alpha-1 converge, where they diverge, and how far the evidence behind each one actually reaches.

## The short version

This page lines up [thymulin](/thymulin) and [thymosin alpha-1](/thymosin-alpha-1) on the dimensions that matter most when reading immunomodulatory research peptides: molecular class, primary study setting, the quality of the evidence, how each was administered in studies, regulatory standing, and the single most important caution for each. The headline finding is asymmetric. Thymosin alpha-1 has the clinical depth — approved in 35+ countries, multiple RCTs including a large Phase 3 trial — while thymulin has the mechanistic precision and the more tightly defined thymic-hormone identity, but is almost entirely preclinical [8][9]. Neither is an approved therapeutic in the United States, and neither should be read as one.

## The comparison matrix

| Dimension | Thymulin | Thymosin Alpha-1 |
| --- | --- | --- |
| Peptide class | Zinc-dependent thymic nonapeptide hormone (9 aa) | N-terminally acetylated 28-aa thymic polypeptide |
| Most-studied in | T-lymphocyte differentiation; neuroendocrine axis; anti-inflammatory CNS and lung models | Sepsis, chronic viral hepatitis, severe COVID-19, cancer adjuvant therapy |
| Evidence base (model) | Mostly rodent; human zinc-deficiency studies only [6][7] | Multiple RCTs including a 2025 Phase 3 trial of 1,106 patients [8][12] |
| Administration studied | Gene-therapy vectors (intratracheal, intracerebral, IP); in vitro; human zinc-status studies [1][4][6] | Subcutaneous injection (clinical standard); IV in some trials [8][9] |
| Regulatory / approval status | Not FDA-approved; research peptide only | Approved as drug (thymalfasin) in 35+ countries; not FDA-approved for US marketing [9] |
| Key caution | Activity is strictly zinc-dependent; almost all evidence is preclinical [5][7] | 2025 Phase 3 TESTS trial was null (HR 0.99, P=0.93); benefit in sepsis not established [8] |

## Peptide class

The two compounds are structurally quite different despite sharing a thymic origin. Thymulin is a nonapeptide — just nine amino acids — whose activity depends entirely on binding a single zinc ion in a 1:1 molar complex; the zinc-free apoform is biologically inert [7]. Thymosin alpha-1 is a 28-amino-acid polypeptide with N-terminal acetylation essential for activity; it carries no metal cofactor and is considerably larger in molecular weight. The zinc requirement in thymulin makes its biology uniquely sensitive to the host's zinc nutritional status — a confound with no equivalent in thymosin alpha-1 research [5][6].

## Most-studied in

Each peptide has a distinct experimental home. Thymulin research centers on T-lymphocyte differentiation in the thymus, the thymus-neuroendocrine axis involving the anterior pituitary, and anti-inflammatory models — particularly LPS-induced inflammation and, most recently, experimental allergic asthma via gene therapy [1][3][4]. Thymosin alpha-1 research is dominated by clinical disease states: chronic viral hepatitis (where the drug was first approved), bacterial sepsis in ICU patients, severe COVID-19 with lymphocytopenia and T-cell exhaustion, and cancer combination immunotherapy [8][10][11].

## Evidence base (model)

The disparity in evidence depth is the most important structural difference between these two compounds. Thymosin alpha-1 has a clinical evidence base spanning four decades, multiple RCTs, and a 2025 double-blind Phase 3 trial involving 1,106 patients — the most rigorous immunomodulatory peptide trial completed to date [8]. That Phase 3 trial returned a null result for sepsis mortality (HR 0.99), which honest reading requires prominently. Thymulin's strongest human evidence is a 1988 zinc-deficiency study demonstrating that thymulin activity tracks zinc status and is restored by zinc repletion in adults [6]. There are no completed controlled clinical trials of thymulin itself for any therapeutic indication.

## Administration studied

Routes follow the research questions. Thymulin in therapeutic studies has been delivered primarily as gene-therapy vectors — intratracheal nanoparticle-plasmid constructs for the asthma model [1] and adenoviral intracerebral injection for CNS studies [4] — along with systemic intraperitoneal administration in mice [3]. The human evidence used intravenous in vitro zinc supplementation and dietary interventions rather than peptide injection [6]. Thymosin alpha-1 / thymalfasin in clinical practice is given by subcutaneous injection, typically on scheduled dosing days; IV dosing has also been studied in sepsis and COVID-19 trials [8][10].

## Regulatory / approval status

Neither compound holds FDA marketing approval in the United States. The regulatory gap is wider than it might appear. Thymosin alpha-1 (thymalfasin) is an approved, internationally prescribed drug in more than 35 countries, with a defined indication, dosing label, and post-marketing pharmacovigilance record [9]. Thymulin, by contrast, has no approved drug form in any jurisdiction — the most advanced delivery systems in the literature are still experimental gene-therapy vectors tested in rodents [1][2]. Material sold as either peptide in the US research market is outside the regulated drug supply chain.

## Key caution

Each compound carries a defining limitation. For thymulin, it is the entanglement of biological activity with zinc status and the near-total absence of controlled human therapeutic data [5][7]. Any thymulin outcome observed in vivo may partly reflect zinc status rather than peptide-specific pharmacology — a confound that has not been resolved in the clinical literature. For thymosin alpha-1, it is the 2025 TESTS Phase 3 trial: 1,106 patients, double-blind, placebo-controlled, and null (HR 0.99, P=0.93) [8]. The prior positive sepsis signals — including the marginally significant ETASS trial — came from smaller, lower-quality studies. The Phase 3 result should recalibrate expectations across all sepsis applications, even if the strongest historical evidence for thymosin alpha-1 (chronic viral hepatitis) is a separate, earlier setting.

---

A data-forward reading desk for thymic immunology research — effect sizes and study designs, not prescriptions.